Health-related quality of life and radioiodine therapy in thyroid cancer patients: a before-and-after study.

Anxiety Depression Health-related quality of life Radioactive iodine Therapy Thyroid cancer

Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
22 Jun 2024
Historique:
accepted: 17 06 2024
medline: 22 6 2024
pubmed: 22 6 2024
entrez: 22 6 2024
Statut: aheadofprint

Résumé

Thyroid cancers are on the rise, but the associated vital prognosis and long-term survival rates are very good. Therefore, treated patients' quality of life and psychological well-being are important considerations. The treatment usually involves surgery and radioactive iodine (radioiodine) ablation. This study aims to investigate potential effects of radioiodine ablation therapy on health-related quality of life, anxiety and depression symptoms, and nutritional status at 6 months post-therapy. This study included 136 patients diagnosed with thyroid cancer. Absorbed doses to the salivary glands were estimated from dosimeters worn by patients. Patient health-related quality of life, psychological status and nutritional status were assessed before and 6 months after therapy using standardized questionnaires (including SF-36, Hospital Anxiety and Depression (HAD) scale). Statistical analyses included random-effects logistic and linear regressions adjusted for potential confounders. While no significant association was found between radioiodine exposure and anxiety or depression symptoms, or nutritional status, a significant increase in the SF-36 role physical sub- score was observed in relation with the salivary gland dose (β= 6.54, 95%CI 2.71;10.36 for a 1-Gy increase). The findings suggest an improved physical health-related quality of life, namely reduced pain and functional impairment, 6 months after radioiodine therapy in thyroid cancer patients. No significant association was found between radioiodine exposure and mental health-related quality of life, anxiety or depression scores nor nutritional status. This study does not provide any evidence that radioiodine therapy has a potentially adverse effect on patient health-related quality of life.

Identifiants

DOI: 10.1007/s11136-024-03721-0 PMID: 38907832
pubmed: 38907832
doi: 10.1007/s11136-024-03721-0
pii: 10.1007/s11136-024-03721-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Pizzato, M., Li, M., Vignat, J., Laversanne, M., Singh, D., La Vecchia, C., & Vaccarella, S. (2022). The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. The Lancet Diabetes & Endocrinology, 10(4), 264–272. https://doi.org/10.1016/S2213-8587(22)00035-3
doi: 10.1016/S2213-8587(22)00035-3
James, B. C., Aschebrook-Kilfoy, B., White, M. G., Applewhite, M. K., Kaplan, S. P., Angelos, P., Kaplan, E. L., & Grogan, R. H. (2018). Quality of life in thyroid cancer—Assessment of physician perceptions. Journal of Surgical Research, 226, 94–99. https://doi.org/10.1016/j.jss.2017.11.069
doi: 10.1016/j.jss.2017.11.069 pubmed: 29661295
De Brauer, C., Bousquet, P. J., & Lafay, L. (2024). [Cancers: Incidence and survival in metropolitan France]. La Revue Du Praticien, 74(1), 30–35.
pubmed: 38329248
Qiao, T., Gao, D., Tong, J., Shen, Y., Ma, J., Lv, Z., & Li, D. (2022). Anxiety and depression status prior to radioactive iodine therapy among differentiated thyroid cancer patients during the COVID–19 pandemic. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 30(12), 10169–10177. https://doi.org/10.1007/s00520-022-07422-7
doi: 10.1007/s00520-022-07422-7 pubmed: 36326909
Maki, Y., Horiuchi, K., & Okamoto, T. (2022). Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease. Endocrine Connections, 11(2), e210506. https://doi.org/10.1530/EC-21-0506
doi: 10.1530/EC-21-0506 pubmed: 35107083 pmcid: 8942325
Goswami, S., Peipert, B. J., Mongelli, M. N., Kurumety, S. K., Helenowski, I. B., Yount, S. E., & Sturgeon, C. (2019). Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. Surgery, 166(1), 69–74. https://doi.org/10.1016/j.surg.2019.01.034
doi: 10.1016/j.surg.2019.01.034 pubmed: 30898373
Andresen, N. S., Buatti, J. M., Tewfik, H. H., Pagedar, N. A., Anderson, C. M., & Watkins, J. M. (2017). Radioiodine ablation following Thyroidectomy for differentiated thyroid Cancer: Literature Review of Utility, Dose, and toxicity. European Thyroid Journal, 6(4), 187–196. https://doi.org/10.1159/000468927
doi: 10.1159/000468927 pubmed: 28868259 pmcid: 5567113
Nguyen, Q. T., Lee, E. J., Huang, M. G., Park, Y. I., Khullar, A., & Plodkowski, R. A. (2015). Diagnosis and treatment of patients with thyroid Cancer. American Health & Drug Benefits, 8(1), 30–40.
Baudin, C., Bressand, A., Buffet, C., Menegaux, F., Soret, M., Lê, A. T., Cardon, T., Broggio, D., Bassinet, C., Huet, C., Armengol, G., Richardson, D. B., Leenhardt, L., Bernier, M. O., & Lussey-Lepoutre, C. (2023). Dysfunction of the salivary and lacrimal glands after Radioiodine Therapy for thyroid Cancer: Results of the START Study after 6-Months of Follow-Up. Thyroid®. https://doi.org/10.1089/thy.2023.0090
doi: 10.1089/thy.2023.0090 pubmed: 37855745
Tagay, S., Herpertz, S., Langkafel, M., Erim, Y., Bockisch, A., Senf, W., & Görges, R. (2006). Health-related quality of life, depression and anxiety in thyroid Cancer patients. Quality of Life Research, 15(4), 695–703. https://doi.org/10.1007/s11136-005-3689-7
doi: 10.1007/s11136-005-3689-7 pubmed: 16688502
Figueiredo, I. R., Dias, S., Taulaigo, A., Vicente, M., Castro, S. G., & Gruner, H. (2023). Editor’s pick: Evaluation of Xerostomia in Sjögren’s syndrome and its impact on Quality of Life and Nutritional Status: A cross-sectional study. EMJ Rheumatol Rheumatology, 2023. https://doi.org/10.33590/emjrheumatol/10303575
August, D. A., Huhmann, M. B., & the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N. &) Board of directors. (2009). A.S.P.E.N. Clinical guidelines: Nutrition Support Therapy during Adult Anticancer Treatment and in hematopoietic cell transplantation. Journal of Parenteral and Enteral Nutrition, 33(5), 472–500. https://doi.org/10.1177/0148607109341804
Watt, T., Christoffersen, T., Brogaard, M. B., Bjorner, J. B., Bentzen, J., Hahn, C. H., Nygaard, B., & Feldt-Rasmussen, U. (2023). Quality of life in thyroid cancer. Best Practice & Research Clinical Endocrinology & Metabolism, 37(1), 101732. https://doi.org/10.1016/j.beem.2023.101732
doi: 10.1016/j.beem.2023.101732
van Velsen, E. F. S., Massolt, E. T., Heersema, H., Kam, B. L. R., van Ginhoven, T. M., Visser, W. E., & Peeters, R. P. (2019). Longitudinal analysis of quality of life in patients treated for differentiated thyroid cancer. European Journal of Endocrinology, 181(6), 671–679. https://doi.org/10.1530/EJE-19-0550
doi: 10.1530/EJE-19-0550 pubmed: 31639771
Gamper, E. M., Wintner, L. M., Rodrigues, M., Buxbaum, S., Nilica, B., Singer, S., Giesinger, J. M., Holzner, B., & Virgolini, I. (2015). Persistent quality of life impairments in differentiated thyroid cancer patients: Results from a monitoring programme. European Journal of Nuclear Medicine and Molecular Imaging, 42(8), 1179–1188. https://doi.org/10.1007/s00259-015-3022-9
doi: 10.1007/s00259-015-3022-9 pubmed: 25771905 pmcid: 4480943
Wang, T. S. (2019). What factors contribute to worse quality of life in thyroid Cancer survivors? Clinical Thyroidology®, 31(5), 201–203. https://doi.org/10.1089/ct.2019;31.201-203
doi: 10.1089/ct.2019;31.201-203
Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., Vera, P., Morel, O., Benisvy, D., Bournaud, C., Bonichon, F., Dejax, C., Toubert, M. E., Leboulleux, S., Ricard, M., & Benhamou, E. (2012). Strategies of Radioiodine Ablation in patients with low-risk thyroid Cancer. New England Journal of Medicine, 366(18), 1663–1673. https://doi.org/10.1056/NEJMoa1108586
doi: 10.1056/NEJMoa1108586 pubmed: 22551127
Baudin, C., Lussey-Lepoutre, C., Bressand, A., Buffet, C., Menegaux, F., Soret, M., Broggio, D., Bassinet, C., Huet, C., Armengol, G., Leenhardt, L., & Bernier, M. O. (2022). Salivary dysfunctions and consequences after Radioiodine treatment for thyroid Cancer: Protocol for a self-controlled study (START Study). JMIR Research Protocols, 11(7), e35565. https://doi.org/10.2196/35565
doi: 10.2196/35565 pubmed: 35867385 pmcid: 9356333
Matsumoto, M., Nakamura, T., Watabe, H., Itoh, M., & Hatazawa, J. (1993). Estimation of organ biodistribution and absorbed dose from external measurement with TLDs in PET studies. Medical & Biological Engineering & Computing, 31(1), S151–S156. https://doi.org/10.1007/BF02446664
doi: 10.1007/BF02446664
Lu, C. C., Dong, S. L., Lin, H. H., Ni, Y. C., Jan, M. L., & Chuang, K. S. (2017). Noninvasive measurement of radiopharmaceutical time–activity data using external thermoluminescent dosimeters (TLDs). Physics in Medicine & Biology, 62(4), N58. https://doi.org/10.1088/1361-6560/aa54a9
doi: 10.1088/1361-6560/aa54a9
Deloar, H. M., Fujiwara, T., Shidahara, M., Nakamura, T., Yamadera, A., & Itoh, M. (1999). Internal absorbed dose estimation by a TLD method for -FDG and comparison with the dose estimates from whole body PET. Physics in Medicine & Biology, 44(2), 595. https://doi.org/10.1088/0031-9155/44/2/021
doi: 10.1088/0031-9155/44/2/021
Deloar, H. M., Watabe, H., Nakamura, T., Narita, Y., Yamadera, A., Fujiwara, T., & Itoh, M. (1997). Internal Dose Estimation Including the Nasal Cavity and Major Airway for continuous inhalation of C15O2, 15O2and C15O using the Thermoluminescent Dosimeter Method. Journal of Nuclear Medicine, 38(10), 1603–1613.
pubmed: 9379201
Nakamura, T., Hayashi, Y., Watabe, H., Matsumoto, M., Horikawa, T., Fujiwara, T., Ito, M., & Yanai, K. (1998). Estimation of organ cumulated activities and absorbed doses on intakes of several labelled radiopharmaceuticals from external measurement with thermoluminescent dosimeters. Physics in Medicine & Biology, 43(2), 389. https://doi.org/10.1088/0031-9155/43/2/013
doi: 10.1088/0031-9155/43/2/013
Snaith, R. P. (2003). The hospital anxiety and Depression Scale. Health and Quality of Life Outcomes, 1, 29. https://doi.org/10.1186/1477-7525-1-29
doi: 10.1186/1477-7525-1-29 pubmed: 12914662 pmcid: 183845
Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Medical Care, 30(6), 473–483.
doi: 10.1097/00005650-199206000-00002 pubmed: 1593914
Lépine, J. P., Godchau, M., Brun, P., & Lempérière, T. (1985). [Evaluation of anxiety and depression among patients hospitalized on an internal medicine service]. Annales Medico-Psychologiques, 143(2), 175–189.
pubmed: 4037594
Leplège, A., Mesbah, M., & Marquis, P. (1995). [Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: The MOS SF-36 (version 1.1)]. Revue D’epidemiologie Et De Sante Publique, 43(4), 371–379.
pubmed: 7667543
Thibault, R., Goujon, N., Le Gallic, E., Clairand, R., Sébille, V., Vibert, J., Schneider, S. M., & Darmaun, D. (2009). Use of 10-point analogue scales to estimate dietary intake: A prospective study in patients nutritionally at-risk. Clinical Nutrition, 28(2), 134–140. https://doi.org/10.1016/j.clnu.2009.01.003
doi: 10.1016/j.clnu.2009.01.003 pubmed: 19223093
El Osta, N., Kanso, F., Saad, R., Khabbaz, L. R., Fakhouri, J., & Osta, E., L (2019). Validation Du SF-36, questionnaire générique De La qualité De Vie liée à la santé chez les personnes âgées Au Liban. Eastern Mediterranean Health Journal, 25(10), 706–714. https://doi.org/10.26719/emhj.19.041
doi: 10.26719/emhj.19.041 pubmed: 31774136
Banihashem, S., Arabzadeh, M., Jafarian Bahri, R. S., & Qutbi, M. (2020). Psychological status and Quality of Life Associated with Radioactive Iodine treatment of patients with differentiated thyroid Cancer: Results of hospital anxiety and Depression Scale and short-form (36) Health Survey. Indian Journal of Nuclear Medicine: IJNM : The Official Journal of the Society of Nuclear Medicine India, 35(3), 216–221. https://doi.org/10.4103/ijnm.IJNM_14_20
doi: 10.4103/ijnm.IJNM_14_20 pubmed: 33082677
Gou, J., Cheng, W., Lei, J., Pan, Q., You, W., Cai, M., Tang, H., Lei, Y., Li, Z., Gong, R., & Zhu, J. (2017). Health-related quality-of-life assessment in surgical patients with papillary thyroid carcinoma. Medicine, 96(38), e8070. https://doi.org/10.1097/MD.0000000000008070
doi: 10.1097/MD.0000000000008070 pubmed: 28930844 pmcid: 5617711
Lubitz, C. C., De Gregorio, L., Fingeret, A. L., Economopoulos, K. P., Termezawi, D., Hassan, M., Parangi, S., Stephen, A. E., Halpern, E. F., Donelan, K., & Swan, J. S. (2017). Measurement and variation in Estimation of Quality of Life effects of patients undergoing treatment for papillary thyroid carcinoma. Thyroid: Official Journal of the American Thyroid Association, 27(2), 197–206. https://doi.org/10.1089/thy.2016.0260
doi: 10.1089/thy.2016.0260 pubmed: 27824301
Lu, L., Shan, F., Li, W., & Lu, H. (2016). Short-term side effects after Radioiodine Treatment in patients with differentiated thyroid Cancer. BioMed Research International, 2016, e4376720. https://doi.org/10.1155/2016/4376720
doi: 10.1155/2016/4376720
Chow, K. Y., Kurumety, S., Helenowski, I. B., Giri, S., & Sturgeon, C. (2021). Association between quality of life and patient-reported complications from surgery and radioiodine in early-stage thyroid cancer survivors: A matched-pair analysis. Surgery, 170(2), 462–468. https://doi.org/10.1016/j.surg.2021.01.022
doi: 10.1016/j.surg.2021.01.022 pubmed: 33648765
Rogers, S. N., Mepani, V., Jackson, S., & Lowe, D. (2017). Health-related quality of life, fear of recurrence, and emotional distress in patients treated for thyroid cancer. British Journal of Oral and Maxillofacial Surgery, 55(7), 666–673. https://doi.org/10.1016/j.bjoms.2016.09.001
doi: 10.1016/j.bjoms.2016.09.001 pubmed: 28648407
Giannoula, E., Iakovou, I., Katsikavelas, I., Antoniou, P., Raftopoulos, V., Chatzipavlidou, V., Papadopoulos, N., & Bamidis, P. (2020). A Mobile app for thyroid Cancer patients aiming to Enhance their quality of life: Protocol for a Quasiexperimental Interventional Pilot Study. JMIR Research Protocols, 9(3), e13409. https://doi.org/10.2196/13409
doi: 10.2196/13409 pubmed: 32167482 pmcid: 7101500
Stajduhar, K. I., Neithercut, J., Chu, E., Pham, P., Rohde, J., Sicotte, A., & Young, K. (2000). Thyroid cancer: Patients’ experiences of receiving iodine-131 therapy. Oncology Nursing Forum, 27(8), 1213–1218.
pubmed: 11013902
Shin, J. H., & Lee, S. Y. (2022). Experiences of Korean patients with thyroid cancer receiving radioactive iodine therapy after total thyroidectomy. Asia-Pacific Journal of Oncology Nursing, 9(3), 161–166. https://doi.org/10.1016/j.apjon.2021.12.010
doi: 10.1016/j.apjon.2021.12.010 pubmed: 35494094

Auteurs

Alix Legrand (A)

Faculty of Medicine, School of Public Health, Sorbonne University, Paris, F-75013, France.
Ionizing Radiation Epidemiology Laboratory (LEPID), Institute for Radiological Protection and Nuclear Safety (IRSN), BP 17, Fontenay-aux-Roses, 92262, France.

Marie-Odile Bernier (MO)

Ionizing Radiation Epidemiology Laboratory (LEPID), Institute for Radiological Protection and Nuclear Safety (IRSN), BP 17, Fontenay-aux-Roses, 92262, France.

Alice Bressand (A)

Ionizing Radiation Epidemiology Laboratory (LEPID), Institute for Radiological Protection and Nuclear Safety (IRSN), BP 17, Fontenay-aux-Roses, 92262, France.

Camille Buffet (C)

Thyroid disease and Endocrine Tumor Department, Sorbonne University, Pitié Salpêtrière Hospital AP-HP, Paris, F- 75013, France.
Sorbonne University, Groupe de recherche Clinique Tumeurs Thyroïdiennes n°16, Paris, F-75013, France.
Biomedical Imaging Laboratory, Sorbonne University, CNRS UMR 7371, INSERM U1146, LIB, Paris, F-75006, France.

Corinne Mandin (C)

Ionizing Radiation Epidemiology Laboratory (LEPID), Institute for Radiological Protection and Nuclear Safety (IRSN), BP 17, Fontenay-aux-Roses, 92262, France.

Fabrice Menegaux (F)

Department of General and Endocrine Surgery, Pitié Salpêtrière Hospital, Sorbonne University, AP-HP, Paris, F-75013, France.

Marine Soret (M)

Biomedical Imaging Laboratory, Sorbonne University, CNRS UMR 7371, INSERM U1146, LIB, Paris, F-75006, France.
Department of Nuclear Medicine, Pitié Salpêtrière Hospital, Sorbonne University, AP-HP, Paris, F-75013, France.

David Broggio (D)

Internal Dose Assessment Laboratory, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France.

Céline Bassinet (C)

Ionizing Radiation Dosimetry Laboratory, Institut de Radioprotection et Sûreté Nucléaire, Fontenay-aux-Roses, France.

Christelle Huet (C)

Ionizing Radiation Dosimetry Laboratory, Institut de Radioprotection et Sûreté Nucléaire, Fontenay-aux-Roses, France.

Laurence Leenhardt (L)

Thyroid disease and Endocrine Tumor Department, Sorbonne University, Pitié Salpêtrière Hospital AP-HP, Paris, F- 75013, France.
Sorbonne University, Groupe de recherche Clinique Tumeurs Thyroïdiennes n°16, Paris, F-75013, France.

Charlotte Lussey-Lepoutre (C)

Sorbonne University, Groupe de recherche Clinique Tumeurs Thyroïdiennes n°16, Paris, F-75013, France.
Department of Nuclear Medicine, Pitié Salpêtrière Hospital, Sorbonne University, AP-HP, Paris, F-75013, France.
PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, F-75015, France.

Clémence Baudin (C)

Ionizing Radiation Epidemiology Laboratory (LEPID), Institute for Radiological Protection and Nuclear Safety (IRSN), BP 17, Fontenay-aux-Roses, 92262, France. clemence.baudin@irsn.fr.
ORCID: 0000-0002-2240-1548

Classifications MeSH